This decision reverses a previous ruling that placed approximately 19 peptides on the more restrictive Category 2 list, effectively banning their use in compounded medications due to potential significant safety risks. The reversal came after significant debate and legal challenges from medical providers and pharmacy groups, who argued that the FDA had not presented sufficient evidence to justify the ban
(PubMed) Sawka AM, Ray JG, Yi Q, Josse RG, Lonn E
All of our regimens will provide a physiologically negligible amount of cyanide well below the EFSAs acute reference dose safety threshold of 20 g/kg of body weight (1,270 g for a 140 lb (63.5 kg) person) per day
26G: The narrowest needle
For the broader research view, see the Glow Stack research guide on each compound's role, study context, and safety notes